Roquefort Therapeutics plc
ROQ.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | £337 | £537 | £2,323 | £900 |
| Short-Term Investments | £0 | £0 | £0 | £0 |
| Receivables | £25 | £158 | £102 | £2,179 |
| Inventory | £0 | -£158 | -£102 | -£2,161 |
| Other Curr. Assets | £0 | £158 | £102 | £2,161 |
| Total Curr. Assets | £362 | £695 | £2,425 | £3,079 |
| Property Plant & Equip (Net) | £45 | £50 | £0 | £0 |
| Goodwill | £282 | £282 | £282 | £282 |
| Intangibles | £5,062 | £5,062 | £5,062 | £1,200 |
| Long-Term Investments | £0 | £0 | £0 | £0 |
| Tax Assets | £0 | £0 | £0 | £0 |
| Other NC Assets | £0 | £0 | £0 | £0 |
| Total NC Assets | £5,388 | £5,394 | £5,344 | £1,482 |
| Other Assets | £0 | £0 | £0 | £0 |
| Total Assets | £5,751 | £6,089 | £7,768 | £4,560 |
| Liabilities | – | – | – | – |
| Payables | £23 | £145 | £68 | £41 |
| Short-Term Debt | £400 | £0 | £0 | £0 |
| Tax Payable | £0 | £0 | £0 | £0 |
| Deferred Revenue | £0 | £0 | £0 | £0 |
| Other Curr. Liab. | £157 | £162 | £211 | £155 |
| Total Curr. Liab. | £580 | £307 | £280 | £196 |
| LT Debt | £0 | £0 | £0 | £0 |
| Deferred Rev, NC | £0 | £0 | £0 | £0 |
| Deferred Tax Liab, NC | £282 | £282 | £282 | £282 |
| Other NC Liab. | £0 | £0 | £0 | £0 |
| Total NC Liab. | £282 | £282 | £282 | £282 |
| Other Liabilities | £0 | £0 | £0 | £0 |
| Cap. Leases | £0 | £0 | £0 | £0 |
| Total Liabilities | £862 | £589 | £562 | £477 |
| Equity | – | – | – | – |
| Pref Stock | £0 | £0 | £0 | £0 |
| Common Stock | £1,357 | £1,292 | £1,292 | £719 |
| Retained Earnings | -£5,265 | -£4,293 | -£2,549 | -£914 |
| AOCI | £4,177 | £4,098 | £4,061 | £367 |
| Other Equity | £4,620 | £4,403 | £4,403 | £3,911 |
| Total Equity | £4,889 | £5,500 | £7,207 | £4,083 |
| Supplemental Information | – | – | – | – |
| Minority Interest | £0 | £0 | £0 | £0 |
| Total Liab. & Tot. Equity | £5,751 | £6,089 | £7,768 | £4,560 |
| Net Debt | £63 | -£537 | -£2,323 | -£900 |